Timing Matters: What the Research Actually Says About Starting Hormone Therapy

Timing Matters: What the Research Actually Says About Starting Hormone Therapy

One of the most useful things I can tell a patient considering hormone therapy isn't "yes" or "no" — it's "when."

For years, the public conversation about hormone therapy treated it as a single yes/no question: is it safe, or isn't it? But some of the more careful research on this topic points to something more specific — that when therapy starts, relative to menopause, may matter as much as whether someone starts it at all.

The idea, in plain terms. This is sometimes referred to as the "timing hypothesis." The concept is that starting hormone therapy closer to the onset of menopause — rather than a decade or more afterward — may be associated with more favorable outcomes, particularly for cardiovascular and bone health. One notable clinical trial specifically compared women who began estradiol therapy earlier in the postmenopausal period against those who started later, and found meaningfully different vascular effects between the two groups.

Why this might be the case. The physiological environment of blood vessels, bone, and brain tissue changes over the years following menopause. Hormone therapy started while tissues are still relatively responsive appears to behave differently than hormone therapy introduced after years of estrogen deficiency have already changed the underlying tissue. It's a reminder that biology doesn't always work in reverse the same way it worked going forward.

Why this got lost in the broader conversation. Some of the early, widely publicized research on hormone therapy didn't separate participants by how long they'd been menopausal before starting treatment — which likely blurred the true risk-benefit picture and contributed to blanket conclusions that didn't hold up as well under closer analysis.

What this means for you: if you're in perimenopause or early menopause and hormone therapy is something you're weighing, that timing may be relevant to the conversation. It's not a reason to rush a decision, but it is a reason not to indefinitely postpone the conversation either, if symptoms or risk factors make it worth having.

At ERAs, we talk through timing as part of every hormone consultation — where you are in the menopause transition, your personal and family history, and what the current evidence actually supports for someone in your specific situation.

If you're wondering whether now is the right time to have this conversation, book a visit. There's no pressure — just information.

— Dr. Jennifer Hwang

Longevity, on your own terms.